HDL-cholesterol: Pro-inflammatory and anti-inflammatory effects

Hellenic Journal of Cardiology

Volumn 45, Issue 5, 2004, Pages 324-330

  Koulouris, Spyridon N ^a,b  

^a EVANGELISMOS HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

Apolipoprotein A I; HDL cholesterol; Lecithin cholesterol acyltransferase; Paraoxonase; Platelet activating factor acetylhydrolase

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CORONARY ARTERY DISEASE; INFLAMMATION; REVIEW;

EID: 5444243705     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Rhoads GG, Gulbrandsen CL, Kagan A: Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. New Engl J Med 1976; 294: 293-298.
2. Miller GJ, Miller NE: Plasma high-density lipoprotein concentration in ischemic heart disease. Lancet 1975;16-19.
3. Castelli WP, Garrison RJ, Wilson PW, et al: Incidence of coronary heart disease and lipoprotein levels. JAMA 1986; 256: 2835-2838.
4. Gordon DJ, Probstfield JL, Garrison RJ, et al: High density lipoprotein cholesterol and cardiovascular disease. Circulation 1989; 79: 8-15.
5. Frick MH, Elo O, Haapa K, et al: Helsinki Heart Study: primary prevention trial with gemfibrozil in middle aged men with dyslipidemia. New Engl J Med 1987; 317: 1237-1245.
6. Rubins HB, Robins SJ, Collins D, et al: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Interventional Trial Study Group. New Engl J Med 1999; 341: 410-418.
7. Sacks FM, for the Expert Group on HDL Cholesterol: The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert Group Recommendations. Am J Cardiol 2002; 90: 139-143.
8. The UK HDL-C Consensus group: Role of fibrates in reducing coronary risk: a UK consensus. Curr Med Res Opin; 20: 241-247.
9. Shah PK, Sanjay K, Nilsson J, Cercek B: Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins. An idea whose time for testing is coming, part I. Circulation 2001; 104: 2376-2383.
10. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-126.
11. Rifai N, Ridker PM: High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 2001; 47: 403-411.
12. Ridker P, Cushman M, Stampfer M, et al: Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
13. Ridker PM, Rifai N, Pfeffer MA, et al: Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839-844.
14. Higgins JP: Chlamydia pneumoniae and coronary artery disease: the antibiotic trials. Mayo Clin Proc 2003; 78: 321-332.
15. Hayek T, Oiknine J, Dankner G, et al: HDL apolipoprotein A-I attenuates oxidative modification of low-density lipoprotein: studies in transgenic mice. Eur J Clin Chem Clin Biochem 1995; 33: 721-725.
16. Navab M, Kama SY, Justin Cooke C, et al: Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000; 41: 1481-1494.
17. Navab M, Hama SY, Anantharamaiah GM, et al: Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000; 41: 1495-1508.
18. Ashby DT, Rye KA, Clay MA, et al: Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Atheroscler Thromb Vasc Biol 1998; 18: 1450-1455.
19. Cockerill GW, Saklatvala J, Ridley SH, et al: High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. Atheroscler Thromb Vasc Biol 1999; 19: 910-917.
20. Baker PR, Rye KA, Gamble JR, et al: Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J Lipid Res 1999; 40: 345-353.
21. Hyka N, Dayer JM, Modoux C, et al: Apolipoprotein A-I inhibits the production of interleukin-1 and tumor necrosis factor-a by blocking contact-mediated activation of monocytes by T-lymphocytes. Blood 2001; 97: 2381-2389.
22. Milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice: potential implications for acute plaque stabilization. Circulation 2001; 103: 3047-3050.
23. Rong JX, Li J, Reis ED, et al: Elevating high density lipoprotein cholesterol in apolipoprotein E deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation 2001; 104: 2447-2452.
24. Sampietro T, Bigazzi F, Dal Pino B, et al: Increased plasma C-reactive protein in familial hypoalphalipoproteinemia. A proinflammatory condition? Circulation 2002; 105: 11-14.
25. Brealey CJ, Walker CH, Baldwin BC: A-esterase activities in relation to the differential toxicity of pirimiphos-methyl to birds and mammals. Pesti Sci 1980; 11: 546-554.
26. Humbert R, Adler DA, Distecke CM, et al: The molecular basis of the human serum paraoxonase activity polymophism. Nature Genet 1993; 3: 73-76.
27. Mackness B, Durrington PN, Mackness MI: Polymorphism of paraoxonase genes and low-density lipoprotein lipid peroxidation. Lancet 1999; 353: 468-469.
28. Shih DM, Gu L, Xia Y-R, et al: Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394: 284-287.
29. Ayub A, Mackness MI, Arrol S, et al: Serum paraoxonase after myocardial infarction. Atheroscler Thromb Vasc Biol 1999; 19: 330-335.
30. Ruiz J, Blanche H, James RW, et al: Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995; 346: 869-872.
31. Serrato M, Marian AJ: A variant of human paraoxonase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995; 96: 3005-3008.
32. Cao H, Girard-Globa A, Berthezene F, Moulin P: Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q>R genetic polymorphism. J Lipid Res 1999; 40: 133-139.
33. Evangelou AM: Platelet-activating factor (PAF): implications for coronary heart and vascular diseases. Prostaglandins Leukot Essent Fatty Acids 1994; 50: 1-28.
34. Imaizumi TA, Stafforini DM, Yamada Y, et al: Platelet activating factor: a mediator for clinicians. J Intern Med 1995; 238: 5-20.
35. Tselepis AD, Dentan C, Karabina SA, et al: PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma: catalytic characteristics and relation to the monocyte-derived enzyme. Atheroscl Thromb Vasc Biol 1995; 15: 1764-1773.
36. Tjoerlker LW, Wilder C: Eberhardt C, et al. Anti-inflammatory properties of platelet-activating factor acetylhydrolase. Nature; 374: 549-552.
37. Theilmeier G, De Geest B, Van Veldhoven PP, et al: HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice. FASEB J 2000; 14: 2032-2039.
38. Quark R, De Geest B, Stengel D, et al: Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001; 103: 2495-2500.
39. Yamada Y, Ichihara S, Fujimura T, Yokota M: Identification of the G994>T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for the coronary artery disease in Japanese men. Metabolism 1998; 47: 177-181.
40. Serebruany VL, Gurbel PA, Murugesan SR, et al: Depressed plasma platelet-activating factor acetylhydrolase in patients presenting with acute myocardial infarction. Cardiology 1998; 90: 127-130.
41. Vohl MC, Neville TA-M, Kumarathasan R, et al: A novel lecithin-cholesterol acyltransferase antioxidant activity prevents the formation of oxidized lipids during lipoprotein oxidation. Biochemistry 1999; 38: 5976-5981.
42. Bielicki JK, Forte TM: Evidence that lipid hydroperoxides inhibit plasma lecithin:cholesterol acyltransferase activity. J Lipid Res 1999; 40: 948-954.
43. Sammalkorpi K, Valtonen V, Kerttula Y, et al: Changes in serum lipoprotein pattern induced by acute infections. Metabolism 1988; 37: 859-865.
44. Van Lenten BJ, Hama SY, de Beer FC, et al: Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cocultures. J Clin Invest 1995; 96: 2758-2767.
45. Ehrenwald E, Chisolm GM, Fox PL: Intact human ceruloplasmin oxidatively modifies low density lipoprotein. J Clin Invest 1994; 93: 1493-1501.
46. Lamb DJ, Leake DS: Acidic pH enables ceruloplasmin to catalyse the modification of low density lipoprotein. FASEB Lett 1994; 338: 122-126.
47. Khovidhunkit W, Shigenaga JK, Moser AH, et al: Cholesterol efflux by acute phase high density lipoprotein: role of lecithin:cholesterol acyltransferase. J Lipid Res 2001; 42: 967-975.
48. Hardardottir I, Moser AH, Fuller J, et al: Endotoxin and cytokines decrease serum levels and extra hepatic protein and mRNA levels of cholesteryl ester transfer protein in Syrian hamsters. J Clin Invest 1996; 97: 2585-2592.
49. Pruzanski W, Vadas P, Browning J: Secretory non-pancreatic group II phospholipase A2: role in physiologic and inflammatory process. J Lipid Mediat 1993; 8: 161-167.
50. Johnson WJ, Bamberger MJ, Latta RA, et al: The bidirectional flux of cholesterol between cells and lipoproteins. Effects of phospholipid depletion of high density lipoprotein. J Biol Chem 1986; 261: 5766-5776.
51. Pruzanski W, Stefanski E, de Beer FC, et al: Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins. J Lipid Res 2000; 41: 1035-1047.
52. Quinn MT, Parthasarathy S, Steinberg D: Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA, 1988: 2805-2809.
53. Kume N, Cybulsky MI, Gimbrone MA Jr. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothehal cells. J Clin Invest 1992; 90: 1138-1144
54. Van Lenten BJ, Wagner AC, Nayak DP: High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation 2001; 103: 2283-2288.
55. Elisaf M: Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 2002; 18: 269-276.
56. Kostoula A, Elisaf M: Fibrates and C-reactive protein. Clin Chim Acta 2002; 328: 197.
57. Shah PK, Kaul S, Nilsson J, et al: Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins. An idea whose time for testing is coming, part II Circulation 2001; 104: 2498-2502.